Genetic markers of early response to lurasidone in acute schizophrenia

PHARMACOGENOMICS JOURNAL · Published 2025-02-20 · DOI 10.1038/s41397-024-00360-z

Free full text

Authors being retrieved — see the publisher record. https://doi.org/10.1038/s41397-024-00360-z

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2025

Related articles

• Cardiovascular prescriber attitudes to pharmacogenomics: a survey by the ESC working group on cardiovascular pharmacotherapy · PHARMACOGENOMICS JOURNAL · 2026 · Same journal
• Impact of low BMI and ABCC2 genotype on the clinical response of sequential anthracycline-taxane chemotherapy receiving breast cancer patients: a hospital-based study · PHARMACOGENOMICS JOURNAL · 2025 · Same journal
• Understanding public perspectives on direct-to-consumer pharmacogenomic testing in the UK: a qualitative study · PHARMACOGENOMICS JOURNAL · 2026 · Same journal
• A functional ancestry-linked regulatory haplotype influences CYP2D6 expression · PHARMACOGENOMICS JOURNAL · 2026 · Same journal
• Effects of CYP3A4, CYP3A5, and ABCB1 genetic variants on tacrolimus metabolism during the early period after kidney transplantation · PHARMACOGENOMICS JOURNAL · 2026 · Same journal
• The association between the number of HLA risk alleles and drug allergy and its implications for HLA screening – a case-control study · PHARMACOGENOMICS JOURNAL · 2025 · Same journal
• Analyzing pharmacogenetics cost effectiveness and savings across common health conditions in the United States · PHARMACOGENOMICS JOURNAL · 2025 · Same journal
• Meta-analysis and review of in silico methods in drug discovery – part 1: technological evolution and trends from big data to chemical space · PHARMACOGENOMICS JOURNAL · 2025 · Same journal
• The association of ABCB1, CYP2C19 and CYP2C9 combined activity with clopidogrel resistance in patients with recurrent ischemic stroke · PHARMACOGENOMICS JOURNAL · 2026 · Same journal
• Large-scale analysis demonstrates the influence of CYP2C19 genotype on specific SSRI side effects · PHARMACOGENOMICS JOURNAL · 2026 · Same journal